Gemma N. Jones

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer

Cristina Cruz, Marta Castroviejo‐Bermejo, Sara Gutiérrez‐Enríquez et al. · Annals of Oncology · 2018 · 410 citations · Full text

The in vitro pharmacology of ZM 241385, a potent, non‐xanthine, A_2aselective adenosine receptor antagonist

Simon M. Poucher, J R Keddie, Parminder Singh et al. · British Journal of Pharmacology · 1995 · 362 citations · Full text

The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models

Stephen T. Durant, Li Zheng, Yingchun Wang et al. · Science Advances · 2018 · 292 citations · Full text

Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial

Stéphanie Lheureux, Mihaela Cristea, Jeffrey P. Bruce et al. · The Lancet · 2021 · 204 citations · Full text

Medicine, Metronomic Therapy, Clinical Trials +7

Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells

Rebecca L. Lloyd, Paul W.G. Wijnhoven, Antonio Ramos‐Montoya et al. · Oncogene · 2020 · 179 citations · Full text